Seelos Therapeutics Inc (NASDAQ:SEEL) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 741,300 shares, a decrease of 21.6% from the May 30th total of 945,900 shares. Based on an average daily trading volume, of 630,500 shares, the short-interest ratio is currently 1.2 days. Currently, 25.6% of the shares of the company are short sold.
A number of brokerages have commented on SEEL. Roth Capital set a $10.00 target price on shares of Savara and gave the company a “hold” rating in a report on Tuesday, May 14th. HC Wainwright set a $12.00 price target on shares of IMV and gave the stock a “buy” rating in a research report on Friday, May 10th.
Shares of SEEL traded down $0.01 during mid-day trading on Thursday, reaching $2.03. The stock had a trading volume of 146,933 shares, compared to its average volume of 2,522,478. Seelos Therapeutics has a 12 month low of $1.32 and a 12 month high of $13.95. The business’s fifty day moving average price is $2.31.
About Seelos Therapeutics
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
Featured Story: Certificate of Deposit (CD)
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.